letter
editor
pathogenesi
coronaviru
diseas
remain
unclear
present
evid
effici
therapeut
pathogenesi
sever
acut
respiratori
syndrom
sar
relat
coronaviru
involv
cytokin
storm
high
serum
level
proinflammatori
cytokin
chemokin
interleukin
tumor
necrosi
factor
tnfalpha
interferongamma
similarli
higher
plasma
level
cytokin
interferon
gamma
induc
protein
monocyt
chemo
attract
protein
macrophag
inflammatori
protein
tnfalpha
found
patient
admit
intens
care
unit
cytokin
storm
syndrom
proport
sever
diseas
proinflammatori
appear
one
key
cytokin
lead
inflammatori
storm
may
result
increas
alveolarcapillari
bloodga
exchang
dysfunct
proinflammatori
cytokin
seem
promin
role
inflammatori
cascad
data
suggest
may
potenti
action
target
cytokin
treat
acut
respiratori
distress
syndrom
ard
report
case
patient
respiratori
failur
link
rapid
favor
outcom
two
infus
antiinterleukin
receptor
inhibitor
tocilizumab
suggest
receptor
inhibitor
treatment
could
decreas
risk
progress
toward
sar
mitig
cytokin
storm
lung
figur
antivir
therapi
lopinavirritonavir
use
oral
begun
maintain
day
accord
local
guidelin
day
sudden
dyspnea
satur
drop
requir
oxygen
supplement
increas
lmin
without
need
artifici
ventil
receiv
two
dose
tocilizumab
mgkg
intraven
dose
hour
apart
good
toler
thereaft
experienc
clinic
improv
rapidli
afebril
gradual
decreas
oxygen
consumpt
fulli
discontinu
day
figur
chest
ct
day
confirm
improv
show
partial
regress
pulmonari
infiltr
ground
glass
appear
figur
creactiv
protein
blood
surrog
marker
cytokin
storm
decreas
mgl
mgl
day
figur
major
chang
observ
circul
lymphocyt
subpopul
tocilizumab
percentag
lymphocyt
found
high
tocilizumab
figur
patient
ultim
clinic
fulli
recov
symptom
recombin
human
antihuman
receptor
monoclon
antibodi
tocilizumab
specif
bind
solubl
receptor
inhibit
signal
transduct
tocilizumab
current
mainli
use
treat
patient
rheumatoid
arthriti
given
everi
week
week
favor
safeti
profil
indic
tocilizumab
juvenil
arthriti
giant
cell
arthriti
recent
cytokin
releas
syndrom
associ
chimer
antigen
receptor
cell
therapi
mainli
rheumatolog
indic
toler
tocilizumab
gener
good
main
advers
event
transient
decreas
leukocyt
increas
liver
enzym
slight
increas
bacteri
infect
patient
safeti
profil
especi
potenti
drug
interact
antivir
remain
investig
clinic
trial
clinic
trial
also
requir
explor
whether
tocilizumab
use
effect
patient
respiratori
failur
due
investig
stage
diseas
treatment
could
appropri
report
first
success
treatment
patient
respiratori
failur
relat
treat
tocilizumab
present
report
sever
limit
first
patient
immunosuppress
cancer
case
therefor
generaliz
noncanc
popul
interestingli
lymphocyt
subpopul
present
high
level
senesc
frequent
observ
cancer
patient
data
shown
extent
could
explain
sensit
tocilizumab
explor
second
patient
receiv
concomit
therapi
especi
lopinavirritonavir
seem
unlik
chang
diseas
trajectori
sinc
lopinavirritonavir
recent
shown
effect
patient
sever
random
control
trial
thu
seem
like
rapid
control
pulmonari
hyperinflamm
result
tocilizumab
treatment
summari
hyperinflammatori
pulmonari
symptom
associ
cytokin
storm
involv
interleukin
chemokin
dysregul
among
action
proinflammatori
interleukin
axi
seem
play
major
role
report
first
observ
patient
sever
lung
diseas
success
treat
antiinterleukin
receptor
treatment
block
cytokin
axi
appear
us
promis
therapi
studi
urgent
patient
develop
sever
acut
respiratori
syndrom
relat
coronaviru
dr
jeanmari
michot
jmm
report
sponsor
research
gustav
roussi
cancer
center
abbvi
agio
amgen
